NO20006457L - Vaksine-indusert hepatitt B viral stamme og anvendelser derav - Google Patents

Vaksine-indusert hepatitt B viral stamme og anvendelser derav

Info

Publication number
NO20006457L
NO20006457L NO20006457A NO20006457A NO20006457L NO 20006457 L NO20006457 L NO 20006457L NO 20006457 A NO20006457 A NO 20006457A NO 20006457 A NO20006457 A NO 20006457A NO 20006457 L NO20006457 L NO 20006457L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
major
surface antigen
amino acid
Prior art date
Application number
NO20006457A
Other languages
English (en)
Other versions
NO20006457D0 (no
Inventor
Chong Jin Oon
Gek Keow Lim
Ai Lin Leong
Yi Zhao
Wei Ning Chen
Original Assignee
Government Republic Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Republic Singapore filed Critical Government Republic Singapore
Publication of NO20006457D0 publication Critical patent/NO20006457D0/no
Publication of NO20006457L publication Critical patent/NO20006457L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Gjennom denne søknad blir ulike referanser henvist til i parenteser. Beskrivelser av disse publikasjoner i deres helheter blir herved inkorporert som referanse i denne søknad for mer fullt å beskrive fagets status som denne oppfinnelsen dreier seg om. OPPFINNELSENS BAKGRUNN Den foreliggende oppfinnelse dreier seg om hepatitt B-virusgenomet vaksine-indusert mutasjon i aminosyreresten 145 (glycin til arginin) i hovedovertlate- antigenet, dets nukleotidsekvens, de avledede fire hovedproteinsekvenser, antigen, antistoff, deteksjonssystemer, utvikling av effektive vaksiner, og anti-virusmidler. Hepatitt B-virus ble først oppdaget i 1963 som et humant virus som blir over- ført parenteralt. Selv om disse virus ikke er spesielt cytotoksiske og ikke fører til massiv celledød, har de vært årsak til en dominerende infeksjonssykdom som affiserer både voksne og unge barn over hele verden. Tilstedeværelsen av hepatitt B overflateantigen har fungert som den viktigste påvisningsmarkør for bærere av hepatitt B-virus, og derved for de som har risk for å overføre viruset. Tilsvarende indikerer forekomst av et anti-overflateantigen antistoff en immunrespons som ville kunne føre til eventuell helbredelse. Stimulering av en slik immunrespons har i betydelig grad blitt hjulpet av de for øyeblikket lisenserte hepatitt B-vaksiner som er utviklet av Merck Sharpe & Dohme. Disse vaksiner inneholder det dominerende overflateantigen enten i den naturlige (plasma-avledet) eller rekombinante (renset fra gjærceller) former, og de har vist seg å være sikre og effektive i å nøytralisere hepatitt B-viruset. l Singapore har det aktive vaksinasjonsprogram som utføres i en nasjonal skala, resultert i en betydningsfull nedgang i akutt hepatitt B-infeksjon, og insidensen i primær levercellekarsinom. Denne nedgang har videre blitt assosiert med en øket immunitet i befolkningen. Den viktigste antigene epitop i hepatitt B-viruset er en meget høyt konservert region som omfatter 23 aminosyrerester og er lokalisert fra aminosyreposisjon 124 til 147 i det dominerende overflateantigen. Denne lille region som er benevnt som den gruppe-spesifikke determinant «a» er funnet i alle subtyper og alle isolater av hepatitt B-virusgenomene. Dets antigene egenskaper synes å være fremkalt av dets fore-
NO20006457A 1998-06-19 2000-12-18 Vaksine-indusert hepatitt B viral stamme og anvendelser derav NO20006457L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG1998/000045 WO1999066047A1 (en) 1998-06-19 1998-06-19 A vaccine-induced hepatitis b viral strain and uses thereof

Publications (2)

Publication Number Publication Date
NO20006457D0 NO20006457D0 (no) 2000-12-18
NO20006457L true NO20006457L (no) 2001-02-16

Family

ID=20429861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006457A NO20006457L (no) 1998-06-19 2000-12-18 Vaksine-indusert hepatitt B viral stamme og anvendelser derav

Country Status (22)

Country Link
US (2) US7038035B1 (no)
EP (1) EP1086232A1 (no)
JP (1) JP2002518013A (no)
KR (1) KR100498117B1 (no)
CN (1) CN1255540C (no)
AR (1) AR020092A1 (no)
AU (1) AU756858B2 (no)
BG (1) BG105065A (no)
BR (1) BR9815912A (no)
CA (1) CA2332173A1 (no)
HU (1) HUP0103258A3 (no)
IL (1) IL140363A0 (no)
IS (1) IS5777A (no)
MX (1) MXPA00012724A (no)
MY (1) MY135991A (no)
NO (1) NO20006457L (no)
NZ (1) NZ508892A (no)
PL (1) PL191312B1 (no)
TR (1) TR200003778T2 (no)
UA (1) UA73475C2 (no)
WO (1) WO1999066047A1 (no)
YU (1) YU80500A (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
AUPQ810900A0 (en) 2000-06-09 2000-07-06 Austin and Repatriation Medical Centre, The Viral variants and methods of using same
CN100355777C (zh) * 2003-02-10 2007-12-19 文洪模 乙型肝炎病毒pre－S突变蛋白及其制备方法与应用
US20060057670A1 (en) * 2004-09-10 2006-03-16 The Chinese University Of Hong Kong Genomic markers of hepatitis B virus associated with hepatocellular carcinomas
WO2006033368A1 (ja) * 2004-09-22 2006-03-30 Advanced Life Science Institute, Inc. Ｂ型肝炎ウイルスｓ抗原の検出法
TW200643171A (en) 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
CN101948932B (zh) * 2010-07-22 2013-04-03 中国人民解放军第三〇二医院 滚环扩增加跨缺口荧光定量PCR检测乙型肝炎病毒cccDNA试剂盒
CN101948933B (zh) * 2010-07-22 2013-04-03 中国人民解放军第三〇二医院 检测石蜡包埋肝组织乙型肝炎病毒cccDNA的试剂盒
RU2586513C1 (ru) * 2015-04-24 2016-06-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ)
RU2603729C2 (ru) * 2015-04-24 2016-11-27 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007024D0 (en) * 1990-03-29 1990-05-30 Imperial College Novel vaccine
US5955089A (en) * 1993-04-20 1999-09-21 Uab Research Foundation Strain selection of pneumococcal surface proteins
GB9401987D0 (en) * 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
US5830759A (en) * 1994-08-18 1998-11-03 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
AU4353897A (en) 1996-09-18 1998-04-14 Board Of Regents, The University Of Texas System Viral defective interfering particles and uses thereof

Also Published As

Publication number Publication date
NO20006457D0 (no) 2000-12-18
HUP0103258A3 (en) 2003-10-28
PL345203A1 (en) 2001-12-03
PL191312B1 (pl) 2006-04-28
AU7795098A (en) 2000-01-05
HUP0103258A2 (hu) 2001-12-28
JP2002518013A (ja) 2002-06-25
KR100498117B1 (ko) 2005-07-01
AU756858B2 (en) 2003-01-23
KR20010106128A (ko) 2001-11-29
MY135991A (en) 2008-07-31
NZ508892A (en) 2004-02-27
US20070026422A1 (en) 2007-02-01
EP1086232A1 (en) 2001-03-28
BG105065A (en) 2001-09-28
UA73475C2 (en) 2005-08-15
CA2332173A1 (en) 1999-12-23
WO1999066047A1 (en) 1999-12-23
IS5777A (is) 2000-12-19
TR200003778T2 (tr) 2001-06-21
AR020092A1 (es) 2002-04-10
IL140363A0 (en) 2002-02-10
CN1255540C (zh) 2006-05-10
BR9815912A (pt) 2002-02-05
YU80500A (sh) 2004-05-12
MXPA00012724A (es) 2003-02-10
US7038035B1 (en) 2006-05-02
CN1304453A (zh) 2001-07-18

Similar Documents

Publication Publication Date Title
RU2280690C2 (ru) Рекомбинантные вирусы гриппа а
Del Val et al. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope
Geeraedts et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling
Nara et al. Neutralization of HIV‐1: a paradox of humoral proportions
Muster et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus
Johansson et al. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition
Planz et al. Specific cytotoxic T cells eliminate cells producing neutralizing antibodies
Ferko et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice
Hilleman Yeast recombinant hepatitis B vaccine
Kuklin et al. Role of mucosal immunity in herpes simplex virus infection
Rajčáni et al. Current developments in viral DNA vaccines: shall they solve the unsolved?
Lifson et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
AU2001250352A1 (en) Recombinant influenza A viruses
NO20006457L (no) Vaksine-indusert hepatitt B viral stamme og anvendelser derav
Wang et al. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus
Bauer et al. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals
Norris et al. CD4+ T helper cells and the role they play in viral control
Zhong et al. CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but has a negative effect on CD8+ T cell memory
Jones et al. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice
Jones et al. Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies
Zhang et al. Anti-neuraminidase immunity in the combat against influenza
Shiraki et al. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen
Wang et al. Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d
WO2022085648A1 (ja) 融合タンパク質及びワクチン
Hainz et al. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of varicella-zoster virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application